METT5D1 Inhibitors
METT5D1 Inhibitors encompass a diverse array of chemical compounds that can influence the activity of METT5D1 through various biochemical and cellular pathways. Staurosporine, for instance, by inhibiting protein kinase C, can alter the phosphorylation status of multiple proteins within the cell. This alteration in phosphorylation can impact various cellular processes, including those that regulate the activity and localization of proteins like METT5D1. Staurosporine's broad kinase inhibition may therefore reduce METT5D1 activity either by direct inhibition or by changing the function of regulatory proteins that interact with METT5D1.
LY294002 and Wortmannin inhibit PI3K, which may reduce Akt-mediated signaling, a pathway that can influence METT5D1 activity or stability.Rapamycin suppresses mTOR activity, which could decrease protein synthesis globally, including that of METT5D1.PD98059 and U0126 inhibit MEK in the MAPK/ERK pathway, potentially reducing the expression of METT5D1 by impacting transcription factor activity. SB203580 inhibits p38 MAP kinase, affecting stress response transcription factors and possibly METT5D1 expression. SP600125 inhibits JNK, which may alter the expression of genes involved in cell cycle regulation and apoptosis, including those that regulate METT5D1. ZM336372 inhibits Raf kinase, affecting the MAPK/ERK signaling cascade and possibly METT5D1 expression. Leflunomide inhibits pyrimidine biosynthesis, which can lead to a decrease in RNA and DNA synthesis, indirectly reducing METT5D1 levels. Geldanamycin binds to Hsp90, disrupting its chaperone function, which may destabilize proteins that regulate or interact with METT5D1. Roscovitine inhibits CDKs, leading to cell cycle arrest and potentially reduced protein synthesis, including that of METT5D1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of a wide range of protein kinases. This compound can inhibit protein kinase C (PKC), which plays a role in the signaling pathways that might indirectly regulate the activity of METT5D1 by modulating the phosphorylation state of proteins involved in the nuclear localization signals (NLS), potentially affecting the import of METT5D1 into the nucleus. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. PI3K is part of the signaling pathway responsible for the regulation of cell survival and apoptosis. By inhibiting PI3K, this compound may lead to the alteration of cellular survival pathways, indirectly leading to a decrease in METT5D1 levels due to increased cellular apoptosis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a key kinase regulating cell growth, proliferation, and survival. By inhibiting mTOR, which is upstream of several translational regulators, rapamycin could decrease the translation of a broad range of proteins, including METT5D1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. This pathway is involved in the regulation of cell division and differentiation. Inhibition of MEK could result in changes in cell cycle progression, potentially leading to reduced synthesis of METT5D1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor with a similar mechanism to PD98059. By inhibiting MEK, U0126 could disrupt the MAPK/ERK signaling pathway, leading to an altered transcriptional program that could indirectly decrease METT5D1 expression by affecting factors that control its transcription. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in stress and inflammatory responses. Inhibition of p38 could affect the phosphorylation of transcription factors that regulate the expression of METT5D1, leading to its reduced synthesis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in cell stress and apoptosis. By inhibiting JNK, SP600125 could affect transcription factors that regulate METT5D1 expression, potentially leading to reduced levels of the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which operates through a mechanism similar to LY294002. By inhibiting PI3K, Wortmannin can lead to the activation of apoptosis and a reduction in cell survival, potentially leading to decreased levels of METT5D1. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a potent inhibitor of Raf kinase, which is part of the MAPK/ERK pathway. Inhibition of Raf could lead to reduced activity of the MAPK/ERK pathway, potentially leading to decreased expression of METT5D1 due to changes in the transcriptional program. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide is an inhibitor of dihydroorotate dehydrogenase, hindering pyrimidine synthesis. This can lead to a decrease in RNA and DNA synthesis, which may result in lower levels of METT5D1, as the synthesis of all proteins could be indirectly affected. | ||||||